Non-small Cell Lung Cancer Clinical Trial
Official title:
Dynamic CT Perfusion for Assessment of Lung Cancer Before and After Neoadjuvant Chemo-/ Radiotherapy
Cancer of the lung is treated with surgery, radiation or chemotherapy, depending on the
stage or extent of the disease. Some patients are treated with chemotherapy and/or radiation
therapy before surgery to improve the results of surgery. After these treatments, we do not
know whether the residual tumour tissue is still alive or dead, which is why some physicians
feel that surgery is required to remove it.
This study is designed to assess if computed tomography (CT, CAT-scan) enhanced with
intravenous contrast agent (dye) can characterize a lung cancer, and say whether it is alive
or dead. The researchers hope that in the future such a contrast-enhanced CAT-scan will make
surgery less often necessary or improve the results of chemotherapy and/or radiation given
before surgery.
The proposed study will be performed in patients with a proven lung cancer for whom
induction therapy and subsequent surgical resection of any kind is planned. Kinetic analysis
of dynamic contrast-enhanced CT will performed using the CT Perfusion 3 software (General
Electric Medical Systems), yielding parameters characterizing tumor microvasculature in
terms of the vascularity, or the blood volume (BV), the tumor perfusion or blood flow (BF),
and the immaturity of the vascular wall, in terms of the microvascular permeability
(permeability surface area, PS).
To test the assumption that dynamic CT-assessed tumor microvascular characteristics
represent reliable, user-independent and reproducible parameters, microvascular values and
parameter maps will be derived from two independent observers. To address the interobserver
variability, each study will be analyzed by the PI and by a second researcher (blinded to
the results of the PI). Kappa-statistics will be used to assess inter-rater concordance.
To test the hypothesis that the microvascular parameters obtained from dynamic
contrast-enhanced CT predict the response to induction therapy, the parameters BV, BF and PS
obtained prior to any treatment will be correlated with the histological result from the
resected specimen (path CR or path non-CR). Spearman correlation will be used to compare
non-parametric histology results with quantitative CT microvascular parameters.
To test the hypothesis that the microvascular parameters obtained from dynamic
contrast-enhanced CT reflect the response to induction therapy, the parameters BV, BF and PS
obtained after completion of induction treatment will be correlated with the histological
result from the resected specimen (path CR or path non-CR). Spearman correlation will be
used to compare non-parametric histology results with quantitative CT microvascular
parameters.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |